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Introduction
The European Seminars in Respiratory Medicine has represented an
outstanding series updating new science in respiratory disease from
the 1990’s up to the early beginning of this 21st century [1,2]. Its aim
is to start a new series updating issues and current science, focusing
on the multidisciplinary approach to patients with respiratory disease
[3]. As such, it represents a unique opportunity for specialists in Res-
piratory Medicine involved in Basic and Clinical Research to discuss
topics and debated problems in medical care, at a top level forum
guided by an expert panel of authors.
The structure of the seminar is based on the following pillars:
• Attendance at the Seminars is strictly limited: selection of participants
is based, in order of priority, on scientific curriculum, age (younger
specialists are privileged), and early receipt of the application form.
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• For each topic is allotted considerable time for presentation and dis-
cussion. The first section is devoted to a series of presentations
(with adequate time allocated for discussion) by an expert panel of
researchers and clinicians. In the second section involves discus-
sions of controversial issues, in a smaller audience format encour-
aging interaction between the panel and audience.
• “Meet the expert” seminars discuss topical subjects in more depth,
utilizing an interactive tutorial.
The Seminar is accredited to provide continuing medical education
(CME) for Italian physicians, with approval of up to 100 participants,
providing 13 CME credits to professionals in the following specialties:
Allergology and Immunology, Anestesiology, Cardiology, Geriatrics,
General Practice, Internal Medicine, Pulmonology, Radiology, Rehabili-
tation, Rheumatology, and Thoracic Surgery.
The seminar faced the hot topic of inhalation therapy with an effec-
tive multidisciplinary approach aimed to evaluate, with particular re-
gard, the determinants of adherence to treatment, representing a crit-
ical issue in the management of chronic airway diseases. In asthma
and COPD, the adherence to treatment, representing a pivotal aspect in
long term care, is usually poor, also according to the Italian Ministry of
Health reports. Therefore, the assessment of the causes of this nega-
tive behavior and a correct approach to try to solve this open problem
represent a very important issue in the long-term management of these
chronic diseases
The objectives of this Seminar were:
• Description of the current situation and open problems in asthma
and chronic obstructive pulmonary disease (COPD).
• Analysis of currently available inhalation drugs and the role played
according to specific phenotype.
• Discussion of the specific role of inhaler devices in patient management.
• Provision of several innovative examples of management ap-
proaches aimed to improve adherence to treatment.
Epidemiology of obstructive lung disease 
and adherence to treatment in asthma 
and COPD in Italy
The first epidemiological parameter, taken into account for health
policies, is mortality. Analyzing twenty years of national statistics, it
has been recently shown that the difference between cardiovascular
and respiratory deaths has decreased in Italy from 479 to 252 per
100,000 from 1990 to 2014 [4]. In such a year, there were 41,397 deaths
for respiratory diseases: of them, 20,181 were due to chronic diseases
of lower airways (429 asthma).
The World Health Organization (WHO) European Detailed Mortality
Database [5] (updated July 2016) indicates that Italy ranks 24th out of 43
countries for age standardized death rate (12.8 per 100,000) due to bron-
chitis /emphysema / other COPD, whilst 10th out of 39 for respiratory failure
(1.5 per 100,000). Differently, Italy ranked third to last out of 43 countries
for age standardized death rate (0.32 per 100,000) due to asthma.
The second epidemiological parameter, taken into account for health
policies, is morbidity. The WHO European Hospital Morbidity Database
[6] indicates that Italy ranks four to last out of 33 countries for in-pa-
tients per 1000 populations due to COPD (1.1) and second to last due
to asthma (0.2). However, the COPD data are very much influenced by
the political decision of many health authorities considering as inap-
propriate a diagnosis of COPD from hospital discharge. Thus, the
analysis of the respiratory diagnoses related groups data in the Min-
istry of Health database [7] shows that, differently from most western
countries, COPD decreased in Italy since 1999 (about 140000 hospital
discharges) to 2014 (about 40000 hospital admissions), whilst the code
“Respiratory failure / Pulmonary edema” increased in the same period
from less than 20000 to near 140000 hospital admissions, overcoming
in 2012 the code “Pneumonia / pleuritis” and thus ranking first among
all respiratory hospital admissions.
Analyzing the relevant epidemiological literature of the period 1960-
2007, it was highlighted a COPD prevalence increase from around 6 to
around 9% [8]. Such figure has continued to increase up to 12.0% in
the WHO European region [9].
The European Respiratory Society spirometry tent data [10] has
confirmed an increasing trend of airflow obstruction by age after 40
years, with an overestimate determined by the wrong fixed ratio crite-
rion vs the correct lower limit of normal criterion. However, the figures
from other information sources tend to under-estimate COPD preva-
lence: e.g. the December 2015 Health Survey organized by National In-
stitute of Statistics (ISTAT), that collected data through at-home ad-
ministered interviews to the components of 60.000 households distrib-
uted throughout the national territory, showed a national prevalence of
3.78%, with wide regional variations (Abruzzo and Sardinia: about 5%;
Trentino Alto Adige about 2.5%).
Also the 2008-2012 Health Examination Survey conducted by the Na-
tional Institute for Health (ISS) showed underestimated values of COPD
prevalence rates: e.g., 5% in men and 3.4% in women aged 50-69 years.
Indeed, the respiratory epidemiological studies carried out by Na-
tional Research Council (CNR) in general population samples living in
Po Delta and Pisa areas since the ‘80s had shown in men prevalence
rates of chronic cough and phlegm over 20% and of medical diagnoses
of chronic bronchitis and emphysema between 5 and 7% [11]. Such
studies were also the basis to ascertain the overlap of asthma, chronic
bronchitis and emphysema, with or without airflow obstruction,
through a Proportional Venn Diagram [12]. At last, the very recent pub-
lication covering a 25-year span [13] has reported a definite increasing
trend for all chronic obstructive respiratory symptoms / diseases, as
well as for airflow obstruction, with the highest increments shown by
allergic rhinitis, usual phlegm, COPD, and airflow obstruction.
It is to note that the Italian Medicine Agency (AIFA) utilizes in its an-
nual report on medicines use in Italy (Rapporto OSMED 2015) the preva-
lence rates for asthma (7.2%) and COPD (3.1%) derived from the Health
Search data base of the Italian Society of General Practice. Such figures
differ from those provided by Eurostat: 4.8% asthma, 5.1% COPD.
The quoted CNR general population studies let us also provide infor-
mation on medicines use as directly reported by interviewed people. Si-
moni et al. [14] showed the following frequencies of habitual and occa-
sional drug use in the Po Delta area: 19.4 and 5.0% in males, 32.0 and
6.1% in females. As a validation, the use of medicines used in the last 48
hours was quite similar between the CNR studies and the data provided
by the National Health Service: 28.1 vs 26.3% in males, 40.1 vs 35.2 in fe-
males. When stratifying by disease category, medicines for broncho-pul-
monary conditions had very low figures for habitual use (less than 5%).
The same Authors later analyzed the data of both the rural area of Po
Delta and the urban area of Pisa [15]. They confirmed a low habitual use
(5.2%) for the broncho-pulmonary therapeutic group. Also, most people
of the general population who reported presence of respiratory symp-
toms/diseases or impaired lung function did not use medicines. The un-
deruse of medicines was lower in the urban than in the rural area.
The 2015 AIFA Report pointed out that the prevalence of the treat-
ment with drugs for airways obstructive syndromes was 13% of the total
enrolled population, with minor variations by gender and latitude, but
increasing by age. AIFA uses for COPD five indicators calculating pre-
scriptive appropriateness and adherence to prescribed treatment:
• Percentage of patients with COPD admission in treatment with in-
haled corticosteroids (ICS) (in 2015: n = 54086; 59.1% of all ad-
mitted with COPD; variation vs previous year = + 3.5%) (Region
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characterize subsets on subsets of such patients, ending with the
single patient”. In this attempt, “personalized medicine” in asthma in-
cludes different approaches to the management of the single patient
taking into account specific clinical and functional findings (such as
types and level of symptoms, frequency of acute exacerbations, comor-
bidities, presence of persistent airway obstruction or small airways in-
volvement) and also specific skills, attitudes and practical issues (such
as adherence to the therapy, knowledge of the disease and patients ex-
pectations) which may be specific for each single patient in terms of
management strategies. In contrast, “precision medicine” focuses
more on the specific etiologic and pathologic background underlying
the disease in each single patient which may require the identification
of specific targets of treatment (e.g., allergen immunotherapy or omal-
izumab in IgE-induced allergic asthma, mepolizumab or reslizumab in
non-allergic eosinophliic asthma, etc.) [19].
This concept has been already considered in the new GINA 2014
guidelines, where it is suggested to distinguish “population-level med-
ication choice” from “patient-level medication choice” [20]. Indeed,
asthma is now defined as a “heterogeneous disease” which includes
different clinical and biologic phenotypes, with the common character-
istics of typical respiratory symptoms, large variability in airway ob-
struction, and of being sustained by a chronic inflammatory process of
the airways. Different phenotypes have been described, particularly
distinguishing “type-2 asthma” with an important eosinophilic inflam-
mation which may be easily detected in blood or sputum samples, from
“non type-2 asthma”, where a neutrophilic or pauci-granulocitic pat-
tern of inflammation may be observed in the airways [21]. These two
different patterns of chronic airway inflammation are well known, and
there are several demonstrations that they tend to remain fairly stable
over time [22,23]. There is also a different response to treatment, with
non-eosinophilic pattern showing a poorer response to inhaled and sys-
temic corticosteroids.
Other important factors not strictly related to the biologic basis of
the disease, such as patient preference and practical issues (ability to
use medication, adherence, cost of treatments) may more often require
to consider different treatment options for the single patient.
Poor control of asthma and therapeutic options
Despite the large diffusion of guidelines for asthma management, re-
cent data demonstrate that the level of asthma control is still poor. Sev-
eral real-life observational studies published in the last 15 years report
an adherence rate ranging from 14 to 50% of the asthmatic subjects ex-
amined. An internet-based asthma survey showed that in Italy the pro-
portion of patients reporting a poor asthma symptom control was higher
than 50% [24], and this proportion remained substantially unchanged in
a 4-years follow-up period [25]. The reasons for this poor adherence are
manifold. In front of an unintentional poor adherence (due to forgetful-
ness, confusion, cost of medications), intentional low adherence (due to
unperceived need, fear of side-effects, or cultural issues) is probably
more relevant, because it is related to the perception of the disease and
to the expectations of the patient from the treatment. In particular, pa-
tients tend to stop asthma treatment when the level of symptom control
has been reached and maintained over a period of time, in the assump-
tion that asthma is not a persistent disease requiring regular treatment.
This concept is difficult to be changed, and despite education and em-
pathic discussion with the patient, the majority of patients intentionally
stop drug use when they do not have symptoms.
This is the reason why different strategies should be considered for
each single patient in order to satisfy the willingness of the patient to
self-manage his/her disease and the need to maintain an adequate
level of treatment.
with highest %: Province of Bolzano, 69.5%; region with lowest %:
Sicily, 48.5%)
• Percentage of patients with COPD admission in treatment with long
acting beta agonist (LABA) w/o long acting muscarinic antagonist
(LAMA) (in 2015: n = 54086; 58.3% of all admitted with COPD; vari-
ation vs previous year = + 4.2%) (region with highest %: Lombardy,
65.9%; region with lowest %: Sicily, 43.7%)
• Percentage of patients in treatment with inhaled corticosteroids
(ICS) without exacerbations (in 2015: n = 1660219; 53.3% of all pa-
tients in ICS treatment; variation vs previous year = -1.9%) (region
with highest %: Province of Bolzano, 71.6%; region with lowest %:
Calabria, 37.2%)
• Percentage of patients in treatment with drugs for airways obstruc-
tive syndromes adherent to the treatment (in 2015: n = 1855184;
13.8% of all patients in treatment with those drugs (37.1% without
occasional users); variation vs previous year = -0.2% (0.7% without
occasional users) (region with highest %: Piedmont, 23.3%; regions
with lowest %: Abruzzo and Campania, 10.4%)
• Percentage of patients in treatment with drugs for airways obstruc-
tive syndromes in occasional treatment (in 2015: n = 1855184; 62.8%
of all patients in treatment with those drugs; variation vs previous
year = 0.5%) (region with highest %: Abruzzo, 69.8%; region with
lowest %: Piedmont, 54.5%).
The analysis of such indicators highlights appropriateness and ad-
herence levels to be improved for several therapeutic areas, with im-
portant variations by region, gender and age-group.
Thus, AIFA pinpoints the importance of achieving optimal appropri-
ateness and adherence levels through the participation of all medical
doctors and allied health professionals, patients and care-givers.
The recent CNR studies on assessment of recommendations (Rec) /
guidelines (GL) application in general practice have shown higher
value of appropriateness according to new GOLD Rec (61.4% vs 35.6%)
and a higher value of over-treatment according to old GOLD Rec (52.8%
vs 25.0%) [16]. GPs’ adherence to treatment in accordance with GOLD
severity classification was higher in the most severe patients than in
the mild ones.
Similar findings were shown for treatment appropriateness fol-
lowing ARIA GL: 57.2% in patients with only allergic rhinitis, 46.3% in
those with combined allergic rhinitis and asthma [17]. Such average
figures depended on disease severity, ranging from 48.5 and 23.1% in
mild intermittent to 88.6 and 95.0% in moderate - severe persistent pa-
tients.
In conclusion, future epidemiological surveys, beside monitoring
traditional indicators (mortality, morbidity, prevalence and incidence of
symptoms / diseases) should also collect information on prescriptive
appropriateness and adherence to prescribed treatment in general pop-
ulation samples in order to find determinants of insufficient treatment
adherence and suggest ways to overcome it.
Analysis of currently available inhalation drugs
and personalized treatment in asthma
What is “personalized treatment” in asthma?
Over the recent few years, much attention has been given to the so
called “personalized therapy” in the management of many respiratory
diseases, including asthma. There is no clear consensus on what this
expression means, especially in terms of difference with “precision
medicine”. According to some Authors [18], personalized medicine is
“the final outcome of a long process of examining a disease, starting at
the population level and using various approaches and disciplines to
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“Flexible” therapy for mild to moderate asthmatic patients
Patients with mild to moderate asthma are now defined as patients
in whom a good control may be reached with step 1 to step 3 level of
treatment, according to GINA guidelines [20]. In these patients who
tend to self-reduce the level of asthma symptoms or to withdraw drugs
when there are no symptoms, a more “flexible” approach to the asthma
management may be suggested, in order to partially comply with the
patients’ expectation, without the risk of a loss in asthma control. Fur-
thermore, the level of activity of the disease is also variable over time,
in relationship with the multiple environmental triggers of asthma.
As needed treatment
Some studies tried to assess if treatment with inhaled ICS or
LABA/SABA (short acting beta agonist) +ICS combinations, used only
when symptoms appear, might be an acceptable option in alternative to
regular treatment with low dose ICS in mild asthmatics. The BEST
study compared the rescue use of salbutamol/budesonide (BDP) in-
halation with the regular use of regular low dose BDP or rescue salbu-
tamol alone [26]. Rescue salbutamol/BDP treatment was as effective
as regular low dose BDP in inducing a 50% reduction of the moderate
exacerbations rate in comparison with salbutamol rescue medication
alone; in addition, rescue salbutamol/BDP was associated with a 75%
reduction in the total dose of ICS administered during all the study pe-
riod, in comparison with regular low BDP use. This observation how-
ever was not confirmed in a similar pediatric population [27] and in
another population with more severe asthma [28]. New randomized
controlled trials are currently in progress, with the aim of definitely
confirm the potential usefulness of rescue ICS/LABA combination use
in these mild asthmatics [29].
Maintenance and reliever therapy (MART strategy)
In moderate-severe patients, low adherence may be associated with
higher risk of moderate-severe asthma exacerbations. The attitude to
reduce or stop regular treatment is frequently observed in these pa-
tients as well, mainly in relationship with the poor knowledge of the
disease and the willingness of self-management. For this reason, the
so-called “maintenance and reliever therapy” (MART strategy) has
been developed, in order to gain an acceptable compromise between
the willingness of the patient to have the lowest possible treatment for
asthma and the efficacy in preventing moderate-severe asthma exacer-
bations. Acute asthma related events are associated with a greater de-
cline in FEV1 in mild recent-diagnosed asthmatic patients, and in these
patients ICS use has been shown to reduce the rate of FEV1 decline
[30]. Several studies have largely demonstrated that budesonide
(BDP) formoterol combination -reviewed in [31]. as low dose mainte-
nance treatment and also as rescue medication in the presence of
symptoms, were able to significantly reduce the rate of moderate-se-
vere asthma exacerbations in comparison with other alternative
strategies including regular use of ICS or ICS/LABA combinations [32].
This approach was possible for the rapid-onset action of the bron-
chodilation obtained with formoterol, which is not much different from
salbutamol under this specific respect. The important effect of this
strategy on the rate of asthma exacerbations may be explained by the
time course of symptoms and rescue medication use in the few 4-5 days
before the occurrence of a moderate-severe asthma exacerbation re-
quiring oral corticosteroids [33]; the increase in the ICS dose during
these days due to the rescue use of the ICS/formoterol combination
may explain the reduction of moderate-severe exacerbations. In addi-
tion, this strategy is associated with a reduction of the mean dose of
ICS administered during the stable phase of the disease (this point is
appreciated by the patient who wont to use the minimally effective dose
of drug) and with a high acceptance by the patient who want to self-
manage their disease.
Obviously, both the aforementioned strategies require that the pa-
tient is a good perceiver of asthma symptoms, in order to “catch” the
minimal changes in symptoms frequency and severity, and then to use
properly the rescue doses of the drugs, leading to a rapid resolution of
the impending exacerbation.
Tailoring therapy in asthma
Personalized medicine (more specifically precision medicine) may
regard some specific asthma pheno-endotypes, which may require an
intervention on the specific mechanism of the disease in each indi-
vidual patient (Table 1).
Allergic asthma is a well-known pheno-endotype: it frequently starts
in early age, is associated with type-2 pattern of airway inflammation
(characterized by blood and/or sputum eosinophilia) and is associated
in general with a good prognosis, although a minority of these patients
may reach a high level of asthma severity which may be uncontrolled
by the usual inhaled drugs. In these patients, allergen-immunotherapy
may be a new option, considering that a recent study has demonstrated
the efficacy of two dose regimen of well standardized allergen extracts
of house dust mite on the prevention of asthma exacerbations induced
by a progressive reduction in the ICS dose [34]. Similarly, in severe al-
lergic asthmatics with pre-specified levels of serum IgE and sensitiza-
tion to perennial allergens, the monoclonal antibody omalizumab is
strongly recommended, due to the high efficacy in improving asthma
control and reducing the frequency of asthma exacerbations [35].
Non-eosinophilic allergic asthma is another pheno-endotype which
may potentially require a specific therapeutic approach. It is well
known that in some patients, mainly affected by mild-moderate
asthma, the airway pathology is sustained by a low Th2-expression in-
flammatory pattern (with neutrophils being often the predominant in-
flammatory cells), which may be less sensitive to corticosteroids.
Steroid-naive symptomatic asthmatic patients with low sputum
eosinophil percentage (<3%) had a very high negative predicting value
for improving FEV1 or bronchial hyperresponsiveness after a one-
month treatment with ICS [36]. At this time, there is no study showing
that bronchodilators only may be used in this subgroup of non-
eosinophilic asthmatic patients, and further well-performed clinical
trials would be recommended [37]. In a limited number of observa-
tions, the response to tiotropium in moderate-severe asthmatics was
related to the percentage of neutrophil but not to eosinophil concen-
tration in the induced sputum [38].
Recently, new biologic drugs with a specific target on some crucial
points of the Th2-driven inflammatory cascade have been developed.
Mepolizumab, Reslizumab and Benralizumab are different anti-IL5
monoclonal antibodies which have been demonstrated particularly ef-
fective on severe eosinophilic asthma. Several studies have shown that
pimeEDITRICE
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Allergic asthma
Anti-IgE (omalizumab)
Allergen – Immunotherapy (AIT)
Non-eosinophilic asthma
Poor response to ICS
Bronchodilators only?
Severe high Th2 expression asthma
Potential targets: IL-5, IL4/IL13, etc.
New biologics
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year, including all asthmatics in Europe is $ 1900, which seems lower
than USA, estimated mean $ 3100 [42]. The socioeconomic burden of
asthma is substantial in Europe and is strongly associated with disease
severity and diminished quality of life [43]. According to a study car-
ried out in Italy [44], the average annual cost of drug treatment for an
adult patient suffering from asthma is about € 1434.
Due to the importance of this disease, expenditure on its treatment
and the current need to keep public health care expenditure in check,
it is necessary to investigate the prescription of antiasthmatic drugs in
terms of appropriateness and sustainability of expenditure using the
real population of local health care units. In recent years, researchers
have pointed to the persistence of problems connected with drug use,
such as choosing the wrong medication, incorrect duration of treat-
ment, inadequate dosage regimens, and undertreatment [45,46]. For
this reason, an analysis was also carried out on the appropriateness of
prescribing for asthmatic patients by general practitioners in a local
health care unit, Milano 2 local health care unit [1]. Based on this
analysis, it has been suggested implementation of better health care
planning and more appropriate prescription practices aimed at opti-
mizing use of health care resources for the treatment of bronchial
asthma. The results of the study should be extended to other re-
gional/national reference local health care units, in order to define and
compare average standard costs per disease and consolidated through
the wide sample considered.
In the context of reduction and optimization of national health care
expenditure has been developed tools for monitoring health care and
drug expenditure, with the aim of controlling expenditure and as-
sessing the achievement of targets in national and regional health
care planning. The local/regional health service units currently have
the following digital databases: personal detail databases, pharma-
ceutical databases, hospital illness databases. These sources and
their integration are a powerful tool supporting conventional methods
used in epidemiological studies [47]. Administrative databases offer
low-cost information and, unlike other systems used for monitoring
and assessment of quality of care, they do not require additional in-
vestment in terms of resources. Data contained in administrative
databases are a by-product of economic and administrative opera-
tions, so characterize patients as “consumers” of health care system
services. Assessment of drug utilization using databases enables us
to determine consumption and prescription terms for an important
sample of the asthmatic population, to define total and per capita
costs for the disease and to suggest policies aimed at implementing
expenditure appropriateness and optimization by detecting bench-
marks between districts, physicians, different time periods, con-
sumption by age and gender, and geographic distribution of the dis-
ease. However, it is important to highlight that use of administrative
databases has some limitations. The main limitation of administra-
tive databases is indeed the lack of clinical data; because they are cre-
ated for accounting purposes, they omit important information on,
e.g., patient lifestyle, symptoms, diagnoses, and intermediate out-
come indicators.
Being able to measure and understand the concept of appropriate-
ness of therapy and drug utilization are not only critical to determining
the effectiveness and safety of a certain drug, but they are also impor-
tant for the creation of programs aimed at improving the quality of drug
use. The appropriateness indicator that was chosen in the analysis was
the number of packs used, because the data sheets for antiasthma prod-
ucts as well as the relevant guidelines, recommend following a daily
dosing regimen in order to achieve and maintain asthma control [41].
In order to assess prescribing medications, indicators of appropri-
ateness were 1-3 packs per year (underdosed, inappropriate), 4-12
packs per year (presumably appropriate), and 13 packs per year
in uncontrolled patients with blood eosinophilia, these drugs may de-
termine a more than 50% reduction in the rate of moderate-severe
asthma exacerbations, with associated significant improvement in pul-
monary function and quality of life [39]. Other biologic drugs with a
specific target on different cytokines, (such as IL4/IL13) with a more
“central role” in the Th2 cascade (Lebrikizumab, Dupilumab, Tralok-
inumab), are in progress, and may represent an important alternative
in this subgroup of severe asthmatics selected according to different
biomarkers (like serum periostin or exhaled nitric oxide) [49].
Conclusions
The aim of asthma management is still to obtain the control of symp-
toms and the reduction in the future risk [20]. To this end, it is im-
portant to consider the characteristics of each single patient, not only
in terms of a potential specific pheno-entotype but also in terms of par-
ticular attitudes, expectations and adherence of the patient. Therefore,
each physician needs to find the best strategy for each single patient.
The inhaled drug currently available (ICS, ICS/LABA ad LAMA) may
allow to choose the best strategy among the different available options
(regular treatment, occasional treatment, MART strategy, etc.), in order
to improve compliance and self-management, reducing the drug
burden and then “tailoring” the approach to the management of
asthma.
Specific molecular targets for intervention are represented by al-
lergic asthma, where allergen immunotherapy (in mild asthmatics)
and anti-IgE monoclonal antibodies (in severe asthmatics) may repre-
sent important specific options, and severe eosinophilic allergic
asthma, where the new currently available anti-IL5 monoclonal anti-
bodies represent an important therapeutic resource in this small group
of uncontrolled patients.
In the future, the personalized therapy will be increasingly more im-
portant in the management of asthma, both using the inhaled drugs
that are currently available, but also using the old and new biologic
drugs with specific biomolecular targets.
Cost/benefit evaluation of different 
treatment approaches
Asthma is a common complex chronic airways disease, with a sig-
nificant burden for the society and for patients’ quality of life. Indeed,
asthma is considered to be one of the major health problems in the
Western world [41]. Patients with asthma can have both short-term
treatment for asthma exacerbations and long-term treatment to obtain
and maintain asthma control [42]. The decision to start regular treat-
ment depends on the severity of asthma at the time of diagnosis, and
on the frequency and severity of exacerbations. A progressive, stepwise
approach to drug therapy is recommended, with selection of the best
options for the individual patient based on disease severity [41].
The concurrent treatment of asthma and its co-morbidities increases
the direct costs of treatment. However, the lack of asthma control asso-
ciated with deficient treatment leads to frequent emergency visits and
hospital admissions, mainly in elderly people, and increases total costs
of asthma management [42].
Although asthma is usually recognized as a costly illness, the total
costs to society (direct, indirect and intangible asthma costs) are diffi-
cult to estimate, mainly due to different disease definitions and char-
acterizations, but also to the use of different methodologies to assess
the asthma socioeconomic impact in different societies. The asthma
costs are very variables from country to country, however, according to
recent analysis, it has been estimated that a mean cost per patient per
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(overtreatment, inappropriate). Indeed, prescription of over 12 packs
per year by the physician may expose the patient to side effects due to
overdosing, with a consequent waste of health care resources. The use
of fewer than four packs per year is also to be considered inappropriate,
because drug treatment must be constant in order to achieve control of
the disease and avoid exacerbations.
Appropriate drug prescribing is of critical importance in order to
achieve therapeutic objectives and to optimize the use of resources in
modern health care systems. Adherence to antiasthmatic therapy is an-
other key aspect. Indeed, adherence is one of the pillars of the patient’s
health management in the control and prevention of progression of the
disease. Adherence can be assessed using the medication possession
ratio indicator (MPR), that is the sum of the days’ supply for all fills of
a given drug in a particular time period, divided by the number of days
in the time period, a patient is deemed to be adherent when their MPR
is 80% [48].
Poor adherence to inhaled corticosteroid therapy is recognized as
contributing to failure of treatment, with a consequent increase in
morbidity, mortality, and consumption of health care resources [1]. In
view of the importance of continuing drug therapy, especially in
chronic diseases such as asthma, it is important to quantify the
number of patients who are genuinely persistent in taking their med-
ications. When taking of medication deviates from the prescribed reg-
imen, situation-specific changes in the risk/benefit ratio can arise,
with a decreased benefit, an increased risk, or both [6]. A number of
studies have demonstrated that inadequate adherence (how far the pa-
tient follows the prescribed regimen of doses and administration inter-
vals) and persistence (duration of time between beginning and dis-
continuing therapy) results in increased morbidity and mortality for a
wide variety of diseases, and at the same time, significantly increases
costs related to health management.
If asthma treatment costs increase, the availability of tools able to
compare data on the use of health care interventions in terms of in-
cremental cost per increment in efficacy clearly become of great im-
portance. It is also necessary to transform such tools in a constant point
of reference for the physicians and the health care policy makers
choices. Appropriate drug prescription and good adherence with the
therapy are of critical importance in order to achieve therapeutic ob-
jectives and to optimize the use of resources in modern health care sys-
tems.
Inhaler devices: A key role in the asthma 
personalized action plan
The prevalence of asthma has increased over the past decades and it
is expected to grow further all over the world. Once diagnosis of asthma
has been made, a successful asthma management aims to control res-
piratory symptoms and exacerbations, most of the time through an ad
hoc inhaler device therapy when needed.
In clinical practice, patient’s involvement by respiratory physicians
has become crucial to improve asthma treatment. It helps patients to
become aware of their disease and it reduces exposure to environ-
mental trigger factors and comorbid conditions that contribute to
asthma severity. On the other hand, self-reported symptom control such
as daily PEF monitoring and quality of life questionnaires helps clini-
cians to estimate asthma severity more accurately. It is indeed common
to misunderstand “asthma severity” with “uncontrolled asthma”.
Asthma severity is based on the level of treatment needed to control
respiratory symptoms, it is evaluated retrospectively and over a long pe-
riod, whereas asthma could be poorly controlled by incorrect inhaler
technique and/or poor compliance to treatment.
Inhaler devices for asthma
Over the past few years it has been recognized the high prevalence
of patients with poorly controlled asthma [49]. Once clinicians have
decided to start patients on new inhaler therapy, three steps should be
taken into account: drug choice, inhaler device choice and patient
training in use of inhaler. Any inhaler device requires a correct inhaler
technique in order for the drug to be delivered properly to the lungs and
to be effective. By contrast inhaler mishandling compromise bron-
chodilatation and/or anti-inflammatory action on the bronchial tree
leading to uncontrolled respiratory symptoms and increased exacerba-
tion risk [50]. Three main types of inhaler devices are available, the
pressurized metered dose inhaler (MDI), the dry powder inhaler (DPI),
and the soft mist inhaler (SMI). MDI was introduced in the 1950s and
consist of a pressurized canister, a metering valve and stem, and a
mouthpiece actuator. It requires that the patient exhales completely be-
fore inhaling the medication, actuates a coordination between simul-
taneous inhalation and device activation immediately after, that in-
spires slowly and continuously during inhalation and finally holds
breath for at least 10 s [51]. An incorrect procedure could deposit the
drug in upper airways causing side effects in the mouth and the
oropharynx. Patients who experience coordination problems often are
asked to use an additional spacer device which most of the times re-
sults in patients lack of compliance because it is cumbersome. DPIs
were introduced in the 1980s to exceed these limits: coordination is not
needed and inhalation should be fast and start immediately. However,
DPIs have different internal resistance and a flow-dependent dose
emission. The turbulent flow depends on the speed of the inhalation
maneuver. There is a minimum threshold energy required to produce
particles with appropriate size able to reach the bronchial tree. Inspi-
ratory flow rates of 30 to 60 L/min are required to disaggregate and
aerosolize the drug when using a DPI device [52]. Some studies have
highlighted that young children and patients with severe airway ob-
struction have experienced problems using a fast inhalation flow. Air-
flow obstruction increases the need for inhaled bronchodilator therapy,
but can decrease the effectiveness of that treatment. In these cases, to
improve aerosol delivery into the lungs, the patient should be encour-
aged to use a slow breathing pattern with a normal tidal volume and an
occasional deep breath using alternative devices [53]. In patients af-
fected from severe asthma not well controlled by high dose inhaled glu-
cocorticoids plus a long-acting beta agonist, it has been shown that
tiotropium could be beneficial [54]. The Respimat SMI is an alterna-
tive to MDIs that forces a drug solution through a series of channels
leading to two nozzles that focus two fluid jets into a precisely calcu-
lated convergence producing a vapor of inhalable droplets. SMIs release
the medication in a soft mist, which lasts in the air about six times
longer than the aerosol from an MDI. The lower velocity of the aerosol
decreases oropharyngeal deposition. The longer duration of the aerosol
cloud increases the window for successful inhalation, thus reducing
problems with co-ordination between actuation and inhalation [55].
Patient education in inhaler use and compliance 
to treatment
Optimizing inhaler use for each individual asthma patient is there-
fore a key point that should be highlighted in clinical practice to im-
prove compliance to treatment. Patients should be trained by experi-
enced people, doctors and nurses should spend enough time to offer
simple and clear instructions. When patients are admitted to hospitals
there is usually plenty of time for doctors and nurses to experience dif-
ferent devices, to teach patient the inhalation technique and to eval-
uate it. Conversely, during follow up visits in clinics it could be the case
that this procedure may be seen as time-consuming and provision of
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Most asthmatic patients, however, can be managed successfully in
primary care according to widely accepted guidelines [66,67]. A bulk of
large, randomized clinical trials have found that, apart from a relatively
small proportion of patients with “difficult asthma” requiring specialist
referral and supervision, the disease may be totally or well controlled by
trigger avoidance and inhaled medications [68,69]. Conflicting with
this possibility, and despite the current asthma guidelines stress the
importance of assessing and enhancing adherence to asthma treat-
ment, medication adherence rates in individuals with asthma are con-
sistently low in practice [66,67].
Adherence and nonadherence to asthma treatment
The benefits of drug therapy for asthma have been well established.
The main goals of adult asthma management are i) to achieve and main-
tain control of symptoms, and ii) to prevent or attenuate asthma exacer-
bations. In a relevant proportion of patients, it is also possible to improve
and maintain pulmonary function and achieve an acceptable level of
physical activity; to avoid the progression towards irreversible airflow ob-
struction, and to prevent deaths from asthma. There is currently no cure
for most types of asthma, and achievement and maintenance of these
goals may depend on appropriate patient education and adoption of flex-
ible self-management programs. Over the past few decades we have wit-
nessed several phases in the development of approaches aimed at en-
suring that patients continue therapy for chronic conditions for long pe-
riods of time. Initially the patient was thought to be the source of the
“problem of poor compliance”. Later, not only the term “compliance” has
mostly been superseded by the term “adherence”, which acknowledges
the patient’s rights to choose to take the prescribed medication or to
follow other healthcare-related advice, and eliminates the concept of
blame if this does not occur [70,71]. In addition, the role of the providers
and other stakeholders was also addressed. Now we acknowledge the
complexity of nonadherence to asthma treatment and we are aware that
a systematic approach is required. The idea of compliance is associated
too closely with blame, be it of providers or patients; thus, the concept of
adherence seems a better way of capturing the dynamic and complex
changes required by many players over long periods of time to maintain
optimal health in people with chronic diseases.
Failure to adhere to a regular management plan for asthma (in-
cluding the regular taking of preventive therapies) results in poor
asthma control which has clinical consequences, such as symptoms
and exacerbation of asthma, and decreased quality of life for the pa-
tients, as well as economic consequences, such as emergency depart-
ment visits and increased hospitalization, resulting in health care re-
dundancy and unnecessary high costs.
Despite nonadherence to prescribed medications is a widely per-
ceived phenomenon, it continues to be a frequent and underscored
problem in patients with asthma even in recent years. The causes for
nonadherence are many, including physical, psychological, cognitive,
sociocultural, and economic issues. There are numerous reasons why
patients do not take their medications properly. For example, some find
the cost of the medications unaffordable while others skip their doses
because they are afraid of possible side effects, and of course some
others are just plain forgetful. In addition, due to the intra-individual
variability of their disease, patients are prone to be confused by the er-
ratic presentation of symptoms. However, better education and auto-
mated reminders can help improve adherence.
Objective measurement of adherence should be implemented when-
ever possible. Review of pharmacy refill data or electronic monitoring of
inhaler actuation may be a preferred method to assess adherence. Edu-
cational programs should be specifically designed to address the unmet
needs and specific reasons for nonadherence for the target population.
written materials such as patient information leaflets or multimedia
methods such as video demonstrations, touch-screen computer or web-
based teaching, could be helpful. There are only few studies so far
looking at the effectiveness of inhaler training. In one small study the
best results were achieved when verbal and written instructions were
provided at the same time [56]. However, any training system should
address different patient education levels, not everyone is able or
willing to read written information or multi-media or touch-screen
computers. Overall, face-to-face demonstration seems to be the most
effective way to train patients. It is worth noting that increasing aware-
ness of the importance of correct maneuvers is a crucial step towards
improving asthma control because patient education has been shown
to improve compliance to treatment [57].
After being trained patient should be enough motivate to both main-
tain proper inhaler technique and to continue on treatment. Some
studies observed that repeated instructions in inhaler technique improve
adherence to therapy and asthma outcome [58]. In real life patients
make several errors with inhalation device, so it is also worth assessing
inhaler technique in different occasions. It could be useful therefore
asking General Pratictioners (GPs) and pharmacists to contribute to mo-
tivate and supervise patients from time to time to give a valid feed-back
to clinicians. Armur et al. demonstrated that a Pharmacy Asthma Care
Program improved outocomes for patients in the community [59].
Conclusions
Evidence from systematic reviews and meta-analyses suggests
equivalence among nebulizers, MDIs, and DPIs for delivery of bron-
chodilators and glucocorticoids when used correctly [60]. Thus, the se-
lection of an aerosol delivery device is usually based upon the prefer-
ence and convenience of the clinician and patient, the ability of the pa-
tient to use the device correctly rather than a clear superiority of one
device over another [61]. Choosing the appropriate inhaler device,
training the patient in inhaler use and providing patient education is
challenging and is meant to be a shared responsibility among physi-
cians, respiratory therapists, nurses and pharmacists. Devices able to
analyze spontaneous inhalation profiles and to provide feedback about
inhalation rate could help clinicians in choosing the optimal inhaler,
but more knowledge is needed to improve these fields [62]. Patient ed-
ucation and involvement is essential to create a partnership between
health care professionals participating in clinical care and patients be-
cause it represents one of the keystones of successful asthma manage-
ment. Despite national and international guidelines there is still little
evidence on the best strategies for implementing recommendations
and there is a need for additional studies about patients personalized
asthma action plan [63].
Adherence to asthma treatment: 
Myth and reality
“DRUGS DON’T WORK in patients who don’t take them.”
“There are all kinds of things you can do to marry literacy with health.”
C. Everett Koop
A recent publication of the European Respiratory Society has pointed
out that asthma is a highly prevalent disorder of the airways that af-
fects people of all ages in all European countries as well. In whole Eu-
rope about thirty million people – children and adults under 45 years of
age – suffer from this disease [64]. Asthma has a relatively low fatality
rate compared to other chronic diseases. According to the latest WHO
estimates, released in December 2016, there were globally 383,000
deaths due to asthma in 2015 [65].
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The participants at the WHO Adherence meeting held in June 2001
concluded that defining adherence as “the extent to which the patient
follows medical instructions” was a helpful starting point [72]. Subse-
quently, the issue of adherence to long-term therapies in a number of
chronic diseases states including hypertension, diabetes, smoking ces-
sation, and asthma has been thoroughly addressed by the WHO [73].
Although most research has focused on adherence to medication, ad-
herence also encompasses numerous health-related behaviors that ex-
tend beyond taking prescribed pharmaceutical agents [74].
Nonadherence to treatment is a common problem that can threaten
patients’ health individually as well as add huge costs to the health care
economics and challenge the efficiency of public health system. In op-
erational terms, the variables of adherence are defined as: “not filling
a prescription”, “not taking medication”, “errors in dosage intervals”,
“reducing doses”, “taking extra doses” and “taking additional nonpre-
scribed medication”. Surprisingly, nonadherence is also common
among patients with difficult asthma. In an interview-based investiga-
tion, it was found that 35% of patients with difficult-to-treat asthma,
who had been referred to specialized centers for assessment, had filled
less than 50% of prescriptions for inhaled fixed-dose combination
therapy, with 88% of them admitting poor adherence after initial denial
[64]. Whereas the types of nonadherence varies from the most fre-
quent ‘dose missing’ to the less common ‘not refill in time’ and ‘stop
taking drugs’, adherence is a complex and multifaceted phenomenon
that may be influenced by a number of factors.
The failure of asthmatic patients to adhere to physician-prescribed
regimens, either pharmacologic or behavioral, has been well docu-
mented in medical literature [75,76]. Poor adherence to asthma med-
ication regimens has been repeatedly demonstrated in both children
and adults, with rates of nonadherence commonly reported from 30 to
70% [70]. Medication regimens for asthma care are particularly vul-
nerable to adherence problems because of their duration, the use of
multiple medications, and the periods of symptom remission. The clin-
ical effects of this nonadherence by asthmatic patients can include
treatment failure, unnecessary and dangerous intensification of
therapy, and costly diagnostic procedures, complications, and hospital-
izations. Inhaler competence, the skill to inhale correctly, is particularly
relevant for asthma medication, as inhaling of drugs requires consid-
erable skill and practice [77]. Even if medication is taken daily, depo-
sition in the lungs will be low with incorrect inhalation technique. Al-
though the measurement of adherence is an important component of
both medical and behavioral interventions to control asthma, relatively
little research has directly addressed the reliability and validity of the
measures most widely used to assess asthma medication compliance.
Common measures used to assess adherence to asthma medications
include direct measures, which confirm the use of medication by as-
saying it in blood, urine, or saliva, or which confirm the ability to use a
medication, such as observed skill in using a metered dose inhaler or
dry powder inhaler. Indirect measures infer use with varying degrees of
reliability, by use of clinical judgment, self-report/asthma diaries, med-
ication measurement, and electronic medication monitors. There are,
obviously, limitations in using these measures due to their low sensi-
tivity and specificity, but their discussion is beyond the purpose of this
review.
Understand and solve the problem of nonadherence
Poor adherence to treatment regimens has long been recognized as
a substantial roadblock to achieving better outcomes for chronically
diseased patients. In general, factors related to or involved in adher-
ence to medications are related to five domains: i) patient-related, ii)
disease-related, iii) therapy-related, iv) health system-related, and v)
social/cost-related. Regression modeling, a statistical technique that
assesses the independent strength of the relationship between two
variables while holding other factors constant, identified the six key
predictors of medication adherence. In order of importance, these in-
clude:
1. Patients’ personal connection with pharmacist and pharmacy staff
2. Patients’ level of information about their health status
3. Patients’ affordance of prescribed medications
4. Patients’ perception of importance to take medications exactly as
prescribed
5. Patients’ level of continuity in health care
6. The extent to which medications may cause adverse side effects.
These predictors point out a variety of routes by which both doctors
and pharmacists can address better health outcomes by informing pa-
tients and their caregivers of the importance of treatment adherence.
Intuitively, the systematic assessment of adherence is of cornerstone
importance, and efforts should be made to ensuring it in as larger as
possible number of asthmatic patients. However, one must take into ac-
count that a number of other factors including inhaler handling, the
persistence of asthma triggers, and the presence of comorbidities in pa-
tients that are unable to reach an optimal or good control of their
asthma should also be addressed by physicians and pharmacists pro-ac-
tively. Hence, the patient should not only understand the concept of in-
haled therapy for asthma control, but also be aware that poor inhalation
technique may be a straightforward determinant of failure of asthma
therapy. Patients with poor or incorrect inhalation technique must be
re-trained by means of direct tuition or freely available videos in the
website. Furthermore, the persistence of asthma triggers is a common
feature of uncontrolled asthma. Thus, efforts should be made to identify
persistent sources (often perennial, domestic and/or occupational) of
sensitizing allergens and nonspecific respiratory irritants including cig-
arette smoking. A short checklist of key questions for the assessment of
adherence and persistent asthma triggers is reported in Table 2.
A recent systematic literature search and meta-analysis has shown
that despite heterogeneity among studies in terms of definitions of ad-
herence and asthma exacerbations, the majority of the high-quality
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Table 2. Checklist for the assessment of adherence and persistent asthma triggers in patients with poor controlled asthma.
Does the patient know what asthma and asthma control are?
Is the patient aware of the concept of inhaled therapy for asthma control?
Is the patient using the appropriate inhaled therapy according to the stage of his/her asthma?
Does the patient take inhaled therapy regularly?
Does the patient handle his/her inhalers correctly?
Does the patient know his/her sensitizing allergens and does he/she avoid exposure?
Does the patient avoid exposure to active/passive smoking and other irritants?
Does the patient avoid the use of detrimental medications?
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Conclusions
The global burden of asthma, a chronic, inflammatory disease of the
airways, is considerable. Its effects include reduced quality of life, lost
productivity, missed school days, increased health-care costs, the risk
of hospitalization and even death. As a rule, medications are used to
treat, cure, and prevent illnesses and their consequences. Although ef-
fective treatments that have been shown to dramatically reduce asthma
morbidity are available, they are effective only when properly used by
patients. Thus, they play a prominent role in the treatment of asthma
and other chronic diseases as well. Failing to adhere to prescribed ther-
apeutic schedules contributes to an array of poor health outcomes in
asthmatic patients. Because human behavior is the necessary interface
between good therapies and therapeutic effectiveness, both clinical re-
searchers and clinicians should be aware of the myriad of factors asso-
ciated with patient adherence. There are numerous reasons for which
patients do not take their medications properly. For example, some find
the cost of medications prohibitive while others skip their doses out to
avoid side effects, and of course some are just plain forgetful of taking
them. However, one should keep in mind that better education and au-
tomated reminders could help improve adherence to prescribed treat-
ment of asthma (Table 3).
There is an urgent clinical need for systematic, proven methods to
assess and address medication nonadherence in patients with asthma.
Large, well designed clinical trials to investigate the efficacy of remote
electronic monitoring and reminder systems to improve adherence are
needed. Inadequate adherence and treatment discontinuation are in-
trinsic to the nature and variability of asthma and good adherence
tends to be associated with lower risk of severe asthma exacerbations.
Poor health literacy has been identified as a major cause of medica-
tion non-adherence, and failing to adhere to prescribed medication
regimens contributes to an array of poor health outcomes.
A comprehensive program of asthma care should include patients’
tuition on the correct of inhalers and self-management plan. In addi-
tion, adherence should be routinely assessed in the real life by inter-
viewing patients, and reviewing prescription and refill frequency. Ad-
herence with controller medication should be encouraged even when
symptoms are mild, infrequent, or absent. Finally, adherence to asthma
treatment should be routinely addressed by using a non-judgemental
approach within the context of a poor adherence before considering a
step-up in the treatment of asthma.
The distance between myth and reality of adherence to prescribed
medication is huge as yet. Despite the relationship between health lit-
eracy and the capacity to learn asthma self-management skills is un-
known, the current evidence supports the concept that an improved
knowledge of the disease may be beneficial in terms of adherence.
Therefore, intervening at the interface between patients’ health lit-
eracy and adherence to prescribed medications may be of strategic im-
portance to overcame the nonadherence of asthmatic patients and its
detrimental effects on their health and wellbeing.
studies consistently reported an association between low adherence
and higher risk of severe asthma exacerbations, both in adults and chil-
dren [78].
Another systematic review evaluated interventions to improve adher-
ence to treatment with inhaled corticosteroids in asthmatic patients by
using components of the chronic care model [65]. This study included
two groups; in the first group, the choice of treatment was actively
shared and negotiated between the patient and the physician; in the
second group, the physician alone selected the treatment regimen. The
results showed that the shared-decision making strategy was associated
with a significant improvement in adherence to inhaled corticosteroids
compared to the physician only decision-making strategy [79].
Health literacy
Medications play a prominent role in the treatment and control of
asthma, and thus failing to adhere to prescribed medication regimens
contributes to an array of poor health and staggering economic burden.
Current evidence from studies in children and adults suggests that in-
adequate health literacy is an important key barrier to asthma knowl-
edge [80,81]. Hence, focusing on nonadherence related to health lit-
eracy in asthmatic patients may yield benefits in term of both human
suffering and economic costs.
Literacy refers to an array of intellectual skills and capabilities, in-
cluding reading, writing, understanding, speech and speech comprehen-
sion, and basic math’s calculations. Health literacy, instead, refers to how
well one applies this broad range of capabilities in the context of health
care. Health literacy has been defined as “the degree to which individuals
have the capacity to obtain, process, and understand basic health infor-
mation and services needed to make appropriate health decisions” [82].
Insufficient health literacy of asthma has been associated with lower
adherence to treatment and worse metered-dose inhaler technique. A
number of studies investigating patients’ adherence to asthma med-
ications reviewed by Rosas-Salazar and coworkers, have linked inade-
quate asthma literacy with poor health outcomes [83].
According to a systematic review by the Cochrane Airways Group,
training patients in self-management of asthma, based on self-moni-
toring of both peak expiratory flow and symptoms coupled with a
written action plan and regular medical review, appeared to improve
health outcomes for adults with asthma. In addition, education on self-
management reduced hospitalizations, unscheduled visits to the
doctor, days off work or school and nocturnal asthma. Improvements in
lung function were also achieved [84]. The Cochrane review also
showed that incomplete approaches such as the use of limited educa-
tion (information only) about asthma do not appear to improve health
outcomes in adults with asthma although perceived symptoms may im-
prove. A “proof of concept trial” found that three 30-minute sessions of
motivational interviewing of asthmatic patients with poor adherence
within a 6 week-period improved inhaled corticosteroid refills and the
asthma control test compared to usual care [85].
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Table 3. Questions to be asked to asthmatic patients to understand how they take asthma medications.
Do you have difficulties in adhering to asthma therapy?
Do you ever forget to take your asthma medicine?
Are you careless about when you take your asthma medicine?
Do you sometimes stop using your inhaler(s) when you feel better?
Do you stop taking or skip your inhaler(s) if it seems to make you feel worse?
Do you take inhaler(s) as rescue medications rather than regularly? 
Do you sometimes skip inhaler doses or skip an asthma medicine entirely because of the cost?
No
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Asthma: Toward a definition of the pillars 
of a correct therapeutic strategy
Main goals of asthma management are: achieve good control of
symptoms maintaining normal activity levels and to reduce the risk of
future exacerbations and fixed airflow obstruction appearance mini-
mizing medication side-effects [20].
The pillars of a correct therapeutic strategy can be summarized as
follows: correct diagnosis, correct treatment, correct adherence to
therapy, correct follow-up.
Correct diagnosis
Clinical and instrumental diagnosis is not always simple in asthma.
However, three are the constant features helping in a correct diagnosis.
1) Bronchial hyperresponsiveness. In absence of bronchial hyperre-
sponsiveness there is not asthma [86]. When anamnesis is sugges-
tive for asthma and spirometry normal a bronchoprovocation test
can be helpful in confirming the diagnosis [87].
2) Airflow obstruction with reversibility acutely or over time. A cor-
rect diagnosis of airway obstruction must be based on a spirometry
with FEV1/FVC value below the lower limit of normal [88] to avoid
misdiagnosis in adults and older patients. Misdiagnosis is possible
when obstruction is considered for FEV1/FVC <75-80% of the pre-
dicted value [87]. Secondly, reversibility of airway obstruction is a
milestone in asthma diagnosis. Moreover, many COPD patients
show changes in airway over 12% FEV1 and 200 mL after short
acting bronchodilator [88,89]. This occurs for many reasons as gas
compression [90] or effect of increased bronchial wall thickness
[89]. For these reasons “Asthma COPD overlap” is considered only
when a bronchodilator response higher than 15% change and 400
mL of absolute value from baseline is present after bronchodilator
[90,91].
3) Airflow obstruction variability. Patterns of obstruction change over
short time in patients [92], so monitoring of airflow obstruction
during time can help diagnosis.
Correct treatment
Asthma treatment must be performed using a control-based asthma
management cycle [93]. In control-based asthma management, phar-
macological treatment is adjusted in a continuous cycle that involves
assessment, treatment and review. Asthma outcomes have been shown
to improve after the introduction of control-based guidelines for many
patients in primary care. Reviewing symptom control, risks of exacer-
bation are reduced [94]. Different therapeutic steps are considered:
from “as-needed” short acting beta agonist use to low and high dose
inhaled corticosteroids with addition of long acting beta-2 agonists and
antileukotriens. When severe asthma occurs (step 4-5) patients need
continuous therapy with high doses of drugs (also with oral corticos-
teroids), Tiotropium and recent biological agents (omalizumab
mepolizumab, etc.).
Correct adherence to therapy
Poor adherence is defined as the failure of treatment to be taken as
agreed by the patient and the doctor. It is very common: 50% of adults
and children do not take controller medications as prescribed. Poor ad-
herence contributes to uncontrolled asthma symptoms, exacerbation
risk and asthma-related death.
Optimal asthma control depends on the selected drug, the device that
is employed and on the removal of factors that reduce patients’ adher-
ence to therapy [95,96]. Proper inhaler technique is an important com-
ponent of effective asthma therapy and patients with evidence of poor
adherence and asthma control should be targeted for a review of their
inhaler technique [97-99].
Correct follow-up
Follow up consultations should take place at regular intervals. Reg-
ular review should assess asthma control considering patient’s
symptom control, exacerbation risk factors, flare-ups, comorbidities.
Inhaler use must be assessed and corrected when necessary.
Follow-up can today utilize devices characterized by smart tech-
nology helping to monitor adherence. They accurately record the time
when each dose was taken, store data over a reasonable time period,
and provide access to adherence data. That’s why “smart technology’’
would improve patient adherence, with possible positive impact on
asthma control.
Clinical and device preference comparisons 
of new versus old fixed-dose combination 
inhalers
Asthma and chronic obstructive pulmonary disease (COPD) are pro-
gressive inflammatory respiratory diseases that affect millions of
people worldwide [100,101]. Asthma is a serious global health problem
with an estimated 300 million affected individuals, predicted to in-
crease to 400 million by 2025 [102]. COPD is the fourth leading cause
of death in the world and predicted to be the third by 2030 [20,103].
This disease is a major cause of chronic morbidity and mortality, with
an estimated 4.5 million annual deaths attributable to COPD over the
next 30 years [103].
The ability to identify poor disease control is a pre-requisite for im-
proving asthma and COPD treatment and management. However, over
the last decade, European studies have shown little apparent improve-
ment in the levels of symptom control [104,105]. Asthma control in clin-
ical practice is suboptimal despite available therapies (Figure 1)
[105,106]. This lack of disease control results in high numbers of patients
exacerbating (Figure 2). Many factors that contribute to suboptimal
asthma and COPD control have been identified, including concomitant
rhinitis, a common co-pathology, and smoking. Equally as important is ap-
preciation of patients’ views and concerns about maintenance therapy
and the level of satisfaction with the prescribed inhaler device [107].
Practical barriers are also often encountered, such as poor inhaler
technique. However, data from randomised controlled trials (RCT) sug-
gests that there are no significant differences between inhaler types,
and national and international guidelines base their recommendations
for inhaler use on these data. Nevertheless, RCTs are generally repre-
sentative of fewer than 5% of the population of patients with asthma
[108]. often excluding typical cases seen in general practice including
smokers, patients with comorbidities, and those that suffer from severe
or unstable disease. Patients participating in RCTs are closely moni-
tored to ensure correct use of inhaler therapy and usually require a
minimal adherence rate for continued participation. This does not re-
flect the situation in the general patient population where adherence
tends to be relatively low.
Real-world evidence corroborates and reinforces the results from
clinical trials using data from multiple sources, including electronic
health care records, claims and billing data, product and disease reg-
istries, and data collected through personal devices and health applica-
tions [109]. This facilitates the inclusion of a broad range of patients
comparable to those typically examined in primary care settings.
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the lung, and in turn effect exacerbations and disease control [113].
Maintaining device consistency and increasing the simplicity of the
treatment regime will help decrease critical errors in inhaler use.
Next generation inhalers, that increase patient ease-of-use, have
been developed to enhance the delivery of drugs to the bronchial tree
and to improve the inhalation technique by reducing the possibility of
making errors while operating the device. Inhaler devices such as the
ELLIPTA® and the NEXThaler® were both found to reduce critical er-
rors compared to other MDI and DPI inhalers [114-117].
The CRITIKAL study identified multiple inhaler errors affecting
asthma control outcomes [100]. One of the top recorded errors was ac-
tuation before inhalation [113]. To combat this error, breath actuated
inhalers (BAI) have been developed. These inhalers were found to in-
crease the odds of asthma control, and decrease severe exacerbation
rates, for patients initiating or increasing ICS therapy [118]. Devices
such as the K-Haler and Synchrobreathe have shown promising pre-
liminary results with increasing lung deposition, efficacy and patient
satisfaction.
Many of the newer devices are reported to be easier to use [114-
117]. However, it is still unknown what this means for both health care
professionals (HCPs) and patients. Studies have shown that the nature
and extent of training required to achieve and maintain device mastery
varies with different devices [118]. With changes in inhaler tech-
nology, drug formulations have also evolved. The recent incorporation
of airway-compatible lipid-based porous particles to keep drug crystals
suspended in the propellant without needing additional excipients, has
resulted in a highly uniform formulation. These formulations have
shown minimal drug crystal-crystal interaction throughout manufac-
turing, storage, and drug delivery, and are stable over time, delivering
consistent doses under a variety of storage or handling conditions. The
effect of inhalation therapy is determined by multiple factors, including
the amount of therapy reaching the lungs and its distribution
throughout the airways [119]. Targeting inhaled drug formulations to
the peripheral airways is not efficient, with most of the formulations
being deposited in the central airways. Reducing the mean particle size
of the inhaled drug increases the fraction reaching the peripheral
areas of the lung [111]. Meta-analysis of RCTs demonstrated that
extra-fine ICS have significantly higher odds of achieving asthma con-
trol with lower exacerbation rates at significantly lower doses than
fine-particle ICS [120]. Real-world studies have shown that extrafine
ICS reduce exacerbations and improve asthma control in patients
starting with higher doses of extrafine-particle size ICS [121].
To further improve outcomes in patients with respiratory disease,
treatment has progressed from monotherapy to combination therapy.
Together with the above-discussed options available to improve asthma
control, finding the perfect combination of easy to use inhaler and drug
formulation can be difficult. Furthermore, not all inhaler/drug combi-
nations are licensed for equal use worldwide
Many studies have investigated inhaler effectiveness for respiratory
disease control. However, the results are conflicting with RCT data,
suggesting DPI use was associated with higher rates of adherence in
patients with asthma, whereas real-world studies find MDIs to be asso-
ciated with better control, treatment stability, and lower exacerbation
rates. For patients with COPD, soft mist inhalers, such as Respimat®,
were more accepted by patients than MDIs and DPIs [122]. A study by
Bender et al. found that the top reason for non-adherent patients to be-
come adherent was if they could feel more immediate effects of the
treatment [123].
Is there are way for patients to identify and rectify their inhaler er-
rors in real time? Technology, such as inhaler compliance assessment
technology, an acoustic recording device attached to the inhaler able to
measure and identify technique errors [124], as well as smartphone
A study by Giraud et al., in patients using metered dose inhalers
(MDI), reported that only 30% were able to perform the correct inhaler
technique [110]. This highlights the importance of evaluating correct
inhaler technique and providing the necessary training to all patients
on inhaler use. More recently, Molimard et al. reported an association
between device mishandling and an increase in observed COPD exac-
erbations [111].
A recent real-world study using the global inhaler technique initia-
tive Helping Asthma in Real People (iHARP) database to identify se-
rious inhaler handling errors found the most common errors to be
failure to exhale before inhalation, insufficient breath-hold at the end
of inhalation, and insufficiently forceful inhalation from the start
[112]. The CRITIKAL study identified specific inhaler errors as critical
errors in patients using both MDI and DPI, based on frequency and as-
sociation with asthma symptom control and exacerbation rates [100].
Due to the heterogeneity and complexity of asthma and COPD, pa-
tients are often prescribed mixed inhaler regimes, such as DPIs for
maintenance and pMDI for reliever therapy. These are liable to confuse
patients due to the very different inhalation techniques needed to use
them correctly. This can impact drug delivery to the target airways of
pimeEDITRICE
Figure 2. Exacerbation rates despite current therapy.
Figure 1. Current asthma control in the UK. p<0.001 (Chi-square)
for differences in asthma control between BTS steps; asthma con-
trol defined using data from patient recorded questionnaires.
GINA, Global Initiative for Asthma.
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add-ons to monitor lung function and track flare-ups, have been devel-
oped. Recent research has shown patients that receive inhaler re-
minders are more adherent than those who did not [125].
Finding an optimal match between the patient and the inhaler device
is an achievable goal. However, all the available data points to a need
for an evidence based approach enabling the caregiver to make a
prompt rational choice. Prospective experimental validation is needed
to confirm the validity.
Analysis of currently available inhalation drugs 
in COPD
Inhalation drugs represent for many years a mainstay in the treat-
ment of COPD. The last recommendations GOLD it is mentioned and
stressed both the role of short and long acting Beta2 drugs (SABAs and
LABAs) and that of short acting and long acting antimuscarinic drugs
(SAMAs and and LAMAs) in the management of COPD. Likewise, the
same text underlines the role of combinations of SABAs and SAMAs,
LABAs and LAMAs in various situations and illustrate as well the bron-
chodynamic effects, their action on the riduction of axacerbations, the
improvement of Dyspnea indexes and that of the quality of life [126].
This last edition of GOLD (IBIDEM) marks also the positive role of the
combinations of the inhaled steroids (ICS) and LABAs in improving
lung functions, health status and in reducing exacerbations of mod-
erate and severe degree. Otherwise it is also reminded that a current
and continuous treatment with ICS increases the risk of Pneumonias
at least in patients with severe COPD. Moreover, it is quoted the role of
the triple association (LABA, LAMA and ICS) in improving the lung
functions, in reducing the number of exacerbations and in improving
the clinical general conditions.
Widening the analysis to other LAMAs it has to be quoted the action
of umeclidinium both versus placebo, tiotropium and glycopirronium
[127,128]. In all these cases umeclidinium showed a more important
bronchodynamic effect, but all the molecules, less placebo, proved to be
endowed of a good activity on the vital parameters. Umeclidinium
demonstrated also a good reliability when coupled to vilanterol. This
combination can easily reach different targets thanks to the compli-
mentary actions of LAMA and LABA that support a complete bron-
chodilatory effect. Similar positive outcomes regarded the Saint-
George Respiratory Questionnaire (SGRQ) along all the time of the
study (169 days) [129]. The combination of umeclidinium125 mcg/vi-
lanterol 25 mcg administered for 52 weeks proved a major preventive
effect against the exacerbations in comparison with umeclidinium 125
alone in a random double-blind placebo controlled study [130]. Another
interesting study [131] compared LABA/LAMA (indacaterol/glycopirro-
nium) with a LABA/ICS (Salmeterol/Fluticasone) with an important
target like the prevention of exacerbations and the combination
LABA/LAMA prevailed against the association LABA/ICS. The role of ICS
in lowering the phlogosis has to be postulated considering the lower
number of exacerbations when a combination of bechlomethasone
dip/formoterol is compared with the action of the formoterol alone and
similarly fluticasone furoate (FF) / vilanterol at the two dosages 100/25
and 200/25 demonstrated a solid bronchodynamic effect with a limited
number of exacerbations [132]. The administration of 3 active sub-
stances such as Bechlomethasone/formoterol FF / glycopirronium
through a single special device represent an impressive attempt to
bring different substances endowed of complimentary actions to the
proper targets in order to get a pharmachodynamic synergy. The study
“Trilogy” [133] seems to give a frank support to this hypothesis. The
triple combination obtained a significant success against the compara-
tive association (BDP/FF) under important points of view: trough FEV1,
SGRQ, burden of exacerbations. It has also to be mentioned a possible
novelty, at least under the molecular point of view, because this sub-
stance, GSK 961081, has a structure where at one extremity it is
present an antimuscarinic part, while at the other extremity it exhibits
a Beta2 stimulant action. So, the same molecule could exert a double
and complimentary action [134]. Molecules like this could indicate a
road to the future.
In summary combinations of LABAs/LAMAs, compared with placebo,
causes improvement in FEV1 of 250-300 ml at peak and 250-300 at
trough. These effects are greater than those obtained with long acting
monotherapies alone. Moreover, important clinical questions are asso-
ciated with these bronchodynamic effects: undoubtedly the treatment
with LAMA/LABA positively influences dyspnea indexes, the complexity
of St. George questionnaire, and reduces the number and severity of
the exacerbations. As these substances are not primarily endowed of an
antinflammatory power one might argue that the stability of airways
reached by means of an effective treatment that leads to an improve-
ment of lung mechanics can allow the patients to better cope with neg-
ative factors that trigger infections and exacerbations. This last point
is also well contrasted with the correct use of ICS/LABA despite the in-
creased risk of non-fatal pneumonias. If an association with LABA/ICS
has a good effect in the prevention of exacerbations the association of
ICS/LABA/LAMA can be, as recently proved, a very important resource in
the inhalation therapy specially in the most difficult cases of COPD.
A real-life observational study on homeopathic 
medicine preventive effect in respiratory tract 
infections
The latest scientific literature found in leading biomedical data-
banks confirms that the trend towards what is referred to as “integra-
tive healthcare” has grown constantly over the last 40 years [135].
There are many definitions of “integrative” healthcare, but all in-
volve combining conventional and complementary approaches in a co-
ordinated way. The use of integrative approaches to health and well-
ness has grown within care settings across the United States. Re-
searchers are currently exploring the potential benefits of integrative
healthcare in a variety of situations, including pain management for
military personnel and veterans, relief of symptoms in cancer patients
and survivors, and programs to promote healthy behavior [136].
As a rule, the use of homeopathic medicines in conventional thera-
pies is seen in a positive light by patients. We used a recent American
analysis, the 2012 National Health Interview Survey, to compare home-
opathy users with supplement users and with those using other forms
of complementary and integrative medicine. Among US adults, 2.1%
had used homeopathy within the past 12 months. Respiratory and eye,
ear nose and throat complaints were those most commonly treated
(18.5%). Homeopathy users were more likely to use multiple comple-
mentary and integrative therapies, and to perceive the therapy as
helpful, than were supplement users. Though US homeopathy use re-
mains relatively uncommon, users perceive it as helpful [135-137]. In
terms of respiratory conditions, a number of different findings in Eu-
rope, and in particular in France and Germany, show that these treat-
ments are well received by patients, providing them with an integrated
approach to handling respiratory problems of viral origin, and espe-
cially influenza-like illnesses [138]. One example is a homeopathic
medicine made from a Korsakovian dilution (200K) of a specific extract
of duck liver and heart. Officially recognized in Italy by the AIFA [139]
and also registered in other countries, such as France, where it has
been authorized since 1944, it is sold in a total of over 80 countries
throughout the world.
pimeEDITRICE
No
n c
om
me
rci
al 
us
e o
ly
[page 26] [Monaldi Archives for Chest Disease 2018; 88:886]
Proceedings
drug delivery to the lungs, depending on the device characteristics, for-
mulation of medication, and ease with which patients can use it
[61,147]. Inhaler efficiency may also be influenced by patients’ prefer-
ence, which in turn affects patients’ adherence with treatment and, in-
deed, long-term control of the disease [149-152]. Thus, the choice of
the inhaler for the patient is just as important as choosing the most ef-
fective medication.
Adherence in COPD
It has been estimated that about half of all users of chronic med-
ication take their medication according to their prescriber’s recom-
mendations [73]. A complicating factor for inhaled medication is that
proper inhaler handling and technique is of paramount importance
resulting in even lower real-world adherence rates compared to other
chronic medications. Adherence rates for asthma and COPD are ap-
proximately 40% [73] but tend to be lower in adolescents and in pa-
tients with lower socioeconomic status [153]. Real-world evidence
demonstrates that poor adherence to asthma and COPD treatment is
associated with an increased number of exacerbations, and hospital
admissions, as well as increased economic burden [154-156]. In ad-
dition, the rate of mortality linked to asthma decreased by 21% for
each additional inhaler prescribed in the prior 12 months, demon-
strating that better compliance can reduce mortality [157]. Similarly,
adherence to inhaled medication is significantly associated with re-
duced risk of death and admission to hospital due to exacerbations in
COPD [158].
Inhaler misuse as a cause of poor adherence 
in asthma and COPD
Many studies have shown a high proportion of inhaler misuse
among patients with asthma or COPD, even in those patients who had
been using their devices for long periods [159-162]. Moreover, no im-
provement over the past 40 years in the use of inhaler devices has been
observed, even though considerable effort has been invested in educa-
tion, training and device development [163]. These results support the
major importance given to inhaler technique as a determinant of treat-
ment effectiveness and, consequently, long-term adherence to respira-
tory inhaled medications.
Current inhaler devices require a complex administration procedure
including dose loading, inhaler priming and breathing maneuver, in
order to ensure maximal benefit of the medication. Multiple steps re-
quire that patients display dexterity and coordination [61,147]. Failure
to follow the instructions may lead to inhalation errors, some of which
reduce, or prevent entirely, deposition of the medication in the lungs
[61,147]. In clinical studies, 50-90% of patients with asthma or COPD
show incorrect inhaler technique [161-166]. In addition, even when
patients are able to demonstrate correct inhaler technique, they may
not maintain this standard at other times [161,162]. Complicating the
situation further is the fact that the capacity for physicians and nurses
to train the patient is often limited. Both time constraints and inade-
quate knowledge amongst health care professionals (HCPs) can lead to
ineffective patient education. In a review of 20 relevant studies, only
28% of doctors and 22% of nurses were able to describe, or perform, all
the critical steps for using inhalers [167].
Some patients appear to be at a greater risk of poor inhalation tech-
nique [166,168]. Some risk-factors relate to the patient: these include
extreme ages (i.e., young children and the elderly), very severe airflow
obstruction, cognitive dysfunction, motor handicap of the upper ex-
tremities; Other risk factors relate to the prescription and delivery of
the treatment: patients who are simultaneously prescribed different
types of devices (e.g., a pMDI and a DPI) tend to use their devices less
In the Cochrane Collaboration review of homeopathic medicine, in-
volving a meta-analysis [140] its preventive effect was found, based on
the cumulative result of the meta-analysis, to be protective, but without
reaching the statistically significant limit (overall risk ratio (RR) =
0.48; 95% CI = 0.17-1.34). Specifically, the first study reported a very
low RR value of 0.15 (indicating an 85% reduction in the risk of getting
sick), although the statistically significant limit was not reached; this
can most likely be attributed to the low number of events (n = 50 pa-
tients in each group), which “enlarged” the confidence limits. The RR
was also protective in the second study (which evaluated 110 patients
treated with Oscillococcinum and 117 treated with placebo) and proved
statistically significant, although it was less noticeable than the RR of
the first study (RR = 0.62; thus, a risk reduction of 38%). In my retro-
spective analysis [141] a significant reduction in the frequency of
onset of RTIs was found in both the group treated with homeopathic
medicine and the untreated groups. The reduction in the mean number
of RTI episodes during the period of observation vs. the year before in-
clusion in the study was significantly greater in the homeopathic-
treated group than in untreated patients (-4.76±1.45 vs -3.36±1.30;
p=0.001). These results suggest that homeopathic medicine may have
a positive effect in preventing RTIs. However, randomized studies are
needed before any firm conclusion can be reached.
The importance of inhaler device in patient 
management
Asthma and COPD are two of the leading causes of morbidity, mor-
tality and economic burden worldwide [20,103]. The World Health Or-
ganization (WHO) estimates that chronic respiratory diseases repre-
sent 5% of total disease burden and 8.3% of chronic disease burden
worldwide, accounting for more than 4 million deaths each year [142].
Unsurprisingly, the economic cost associated with asthma and COPD is
considerable, and has been shown to increase with disease severity
[20,103,142,143]. Therefore, effective treatment and management of
asthma and COPD is critical in improving clinical and economic out-
comes.
Inhalation therapy is the mainstay of treatment in patients with
asthma or COPD, where bronchodilators (β2 agonists, anti-muscarinic
agents) and anti-inflammatory drugs (corticosteroids) are recom-
mended by international strategy documents at any stage of the disease
[20,103]. Inhaler devices, therefore, play a key role in the management
of these patients and it is now recognized that the choice of the in-
halation device appears to be as important as that of the drug molecule
[144]. However, in daily clinical practice, while doctors usually focus
on the pharmacological properties of the various respiratory drugs in
selecting the best possible therapeutic option, little consideration is
given to the features of the different inhalers and to the ability of the
patient to use the device [145]. Indeed, it is often underappreciated
that incorrect inhalation technique by the patient is directly associated
with increased healthcare resource utilization [146].
Therapeutic aerosols can be generated essentially by three different
delivery platforms: the pressurized metered dose inhaler (pMDI) where
the drug is formulated in solution or suspension under pressure in a
liquid propellant, and is released through an orifice upon device actua-
tion; dry powder inhalers (DPIs), where the drug is formulated as a
powder that is fluidized and entrained as aerosol particles by the pa-
tient’s own inspiratory effort; nebulizers, for which the drug is formu-
lated as a liquid and atomized into droplets using either a compressed
air source attached to a narrow orifice to generate a Venturi effect or
by more complex vibrating membranes [61,147]. Each type of inhaler
device has pros, as well as, cons [148] and differs in its efficiency of
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appropriately than those using a single device type [169,170], and de-
vice switching without a face-to-face review is associated with wors-
ening of asthma control [170,171].
Strategies to improve patients’ inhaler use
Ways to improve patients’ adherence with inhalers are progressing in-
haler design and use, training patients and individualizing inhaler choice.
Developing the “ideal inhaler”
The ideal inhaler should be user-friendly, deliver the optimal respirable
amount of drug irrespective of the patient’s skills, with limited need for
external supervision and independently of environmental conditions. To
date, none of the currently available inhalers can be considered “perfect”
regarding these characteristics. Although some new inhalers simplify re-
quired dose preparation manipulation [148], patients still need some
training and regular checking of inhalation technique. In addition, the
multiplication of inhalation devices and corresponding instructions can
be a source of confusion for HCPs who are not specialized in the respira-
tory area, such as many primary care physicians, even though they care
for the majority of patients with asthma or COPD [172].
Checking and training
Several studies have shown that training patients in the correct in-
haler use improves not only inhalation technique but also adherence to
treatment and, most importantly, disease control [173-175]. Interest-
ingly, studies found that disease outcomes improved only in those pa-
tients in whom inhaler technique improved following training by phar-
macists, suggesting that the effect of training on control may actually
be determined by the effect on inhaler technique [174,175]. However,
it has also been shown that the effect of training is inconsistent and,
sometimes, transient [176]. Several tools and strategies can be used to
train both patients and HCPs in the correct use of inhaler devices
[177]. Of note, some of them have been developed to help HCPs in
checking inhalation technique and training patients since they provide
real-time, interactive sensory feedback of the patient’s performance in
various critical aspects of inhalation technique, and estimate with rea-
sonable accuracy the amount of aerosol delivered to the receptor sites
[177]. It is important to recall that all HCPs (primary care physicians,
lung specialists, nurses, physiotherapists, pharmacists) can be in-
volved in training. In all cases, regular observation of the patient’s own
technique using his/her inhaler, demonstration of proper technique
when necessary, followed by repeated observation of the patient ability
to correct his/her technique should be considered an essential part of
each patient consultation. More recently, evidence-based digital health
solutions, such as monitoring systems based on phone applications
(Apps) and electronic sensors have been developed to help patients
with their care management via electronic dose counting, calendar re-
minders and in the measurement of physiological parameters [177].
Personalizing device choice
All patients with asthma or COPD do not require the same treatment,
and all do not have the same skills and preferences. Therefore, tailoring
the treatment to each specific patient is of utmost importance
[159,177,178]. Several factors have to be taken into account when se-
lecting a specific inhaler device for a specific patient.
These factors can be categorized as:
1. Patient-related factors, including i) age and ability to inhale con-
sciously, handle the device and coordinate the use of the device and
the inspiratory effort, ii) patient preference, iii) presence of comor-
bidities;
2. Disease-related factors, since i) severe and/or acute airflow obstruc-
tion may compromise the ability to generate an adequate inspiratory
flow and ii) therapeutic strategy and indications are not the same for
asthma and COPD;
3. Device-related factors, as the optimal inhalation profile differs be-
tween pMDIs (slow inspiration is preferable) and DPIs (fast flow in-
halation is required). For instance, observational comparative effec-
tiveness studies suggest that pMDIs delivering small droplet aerosols
could improve treatment effectiveness compared to standard pMDIs
[179], due to the more limited influence of errors in coordination/in-
halation technique on lung deposition with these devices; and, fi-
nally;
4. Caregivers-related factors, accounting for the availability and knowl-
edge of professionals involved in information and education.
Conclusions
Despite the range of effective pharmacological treatments available
for asthma and COPD, many patients still do not achieve treatment
goals, in part because of poor adherence to therapy. Non-adherence to
treatment is associated with poor symptom control, higher healthcare
utilization and healthcare costs, and reductions in health-related
quality of life.
The inhaled route remains favored for the treatment of pulmonary
diseases. However, drug deposition and subsequent treatment effec-
tiveness are highly dependent on inhalation technique, which has been
shown to be incorrect in many patients with asthma and COPD. Many
inhalation devices are available and others are currently being devel-
oped with the aim of simplifying device use. Nonetheless, at present
proper training and regular checking of inhalation technique remain
critical to optimize treatment effectiveness. Optimizing treatment ef-
fectiveness also requires tailoring the drug-device combination chosen
for each individual patient based on their individual characteristics,
the disease treated and its severity, the characteristics of devices and
the skills of involved healthcare professionals.
Influence of comorbidities on adherence 
to treatment in COPD
Patient adherence to treatment in chronic respiratory diseases as
COPD is essential to optimize disease management. As with all chronic
diseases, non-adherence in patients with chronic respiratory diseases
is common and contributes to adverse health outcomes, reduced
quality of life, increased morbidity, increased health care expenditures,
unnecessary escalation in therapies and even hospitalizations and
mortality [180-183].
In 2001, WHO defined adherence as the “extent to which a person’s
behavior taking medication, following a diet, and/or executing life style
changes, corresponds with agreed recommendations from a health care
provide” [73]. In this concept adherence is a complex concept, influ-
enced by multiple factors including social and environmental, patient
related and treatment related factors. Comorbidities are identified as
one of the patient-related factors, besides health beliefs, cognitive
ability, self-efficacy, psychological aspects and others [73].
More recently, the term concordance has been introduced to describe
the therapeutic alliance between patients and health care providers
[184]. Concordance encompasses the responsibility and decision-
making contribution of both parties and empowers the patient to play
an active role in disease management [1].
Multimorbidity is now widely recognized as a characteristic finding in
many patients with Chronic respiratory diseases as COPD. Different
studies have identified a wide spectrum of pathologies in these patient
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There are several approaches, such as biochemical evaluation of
drug level to confirm the intake, electronic monitoring, adherence
measured as the percentage of doses taken/doses prescribed, electronic
monitoring, canister weight, and analysis of pharmacy records to as-
sessing adherence of patients with COPD, but they are all burdened
with important limitations [201]. It is also possible to indirectly
measure adherence by using self-reported (questionnaires) adherence
methods. It has been reported that although the prevalence of treat-
ment adherence changes over time, the combination of the attitude to-
wards treatment and the patient’s knowledge of COPD is the best ap-
proach to test self-reported adherence [202]. However, it must be
pointed out that self-reporting is frequently inaccurate and has mod-
erate reliability (25%-67%) when compared against more objectives
measures of adherence such as canister weight and electronic moni-
toring [203].
Patients, physicians and society influence patient maintenance
medication adherence in COPD. Low expectation of the medication,
presence of comorbid illnesses, depressed mood, increased age, cur-
rent smoking, and lack of confidence in the provider are the most con-
sistent independent predictors of low adherence [204]. Adherence to
medications may be impacted by factors that do not change regardless
of disease or medication type but reasonably is influenced by aspects of
patient-related considerations (forgetfulness, suboptimal health
knowledge, etc.), although also the health system (lack of coordinated
health care, access restrictions, etc.) and socioeconomic status (edu-
cation, income, etc.) can play a role [205]. In particular, the psycholog-
ical profile is a key driver in determining adherence to medications in
COPD patients [206]. Older age coupled with memory loss and im-
paired cognitive levels lowers adherence to medications, in particular
to inhalation therapy [207].
The physician can affect adherence in COPD with his/her prescrip-
tion because medication class to be administered, method of adminis-
tration, dosing regimen, polypharmacy, and also the possible occur-
rence of adverse events can all influence compliance to prescribed
therapy, although patient preference must always be considered a cru-
cial factor when choosing drug, method of administration, and dosing
regimen [208].
It is intriguing that a study performed in an area with a centralized
management system of pharmacological prescriptions and aimed to
assess the degree of adherence for once-daily and twice-daily regi-
mens for administrating LAMAs, showed that adherence to treatment
with LAMAs is very high, irrespective of the molecules or inhalation
device, but did not find that patients who used twice-daily medication
had a lower adherence [209]. The method of administration can af-
fect the level of drug adherence in COPD. There is solid evidence that
in COPD, adherence to inhalation medication is device-related [210].
Often physicians switch their patients to generic inhaled drugs to re-
duce costs. Switching from one device to another, if not accompanied
by appropriate training for the patient, can be associated with poor
clinical outcomes and increased use of health care resources [211].
Additionally, clinician’s confidence about a patient’s adherence to one
class of medication should not be used as a proxy for adherence to
other medications; rather, clinicians should inquire about adherence
to each drug separately [212]. Frequently, health care systems create
barriers to adherence by limiting access to health care, using a re-
stricted formulary, switching to a different formulary, and having pro-
hibitively high costs for drugs, co-payments, or both [213]. Socioeco-
nomic status is an intriguing factor in the search for determinants of
population-level non-adherence to COPD because of its associations
with economic, social, and education-related factors [73]. Care-
givers, especially spouses, may improve therapeutic adherence in
COPD [214].
[184,185]. Polypharmacy is a common finding in these patients as med-
ication is prescribed for all these identified medical conditions. This
polypharmacy is a common and important contributor to poor adherence
as each medication has a different dosing pattern. Patients get frustrated
by these complicated dosing regimens [186]. Many of these drugs have
no immediate or direct effect on symptoms and can have some side-ef-
fects. All these factors can contribute to poor adherence [187]. Concep-
tual frameworks are described to manage comorbidities beyond the
lungs, but most of these reviews summarize current evidence but are not
supported by real-life interventions [188]. Furthermore, adequate sys-
tematic diagnostic work-up according standard criteria is crucial to avoid
under- or overtreatment of these multimorbidities [189].
Pulmonary rehabilitation aims to offer a comprehensive interven-
tion based on thorough patient assessment followed by patient-tailored
therapies, including behavior change, in order to achieve improvement
in physical and psychological condition and to promote long-term ad-
herence to health-enhancing behaviors [190]. Different studies, re-
viewed by Franssen and Rochester, have tried to assess the possible in-
fluence of comorbidities on outcome of pulmonary rehabilitation
[191]. In a retrospective study, Crisafulli et al. identified that the im-
provement in exercise tolerance and quality of life may depend on iden-
tified comorbidities: metabolic diseases were inversely related to im-
provement in exercise tolerance with opposite effects of cardiac dis-
eases. Otherwise, improvements in health status were inversely related
to heart diseases [192]. In another prospective study, the same authors
concluded that the individual’s disability and presence of osteoporosis
were independently associated with poorer rehabilitation outcomes
[194]. Others reported that baseline status is a poor predictor of re-
sponse to rehabilitation, although severely dyspneic patients showed
smaller magnitudes of improvement [195].
Psychological factors are important determinants of outcome and ad-
herence to pulmonary rehabilitation. Risk of drop-out during rehabili-
tation is significantly greater in depressed versus non-depressed pa-
tients and anxiety is associated with worse exercise performance,
quality of life and shortness of breath in COPD patients [195-197]. A
more recent study reported that common comorbidities, including anx-
iety and depression, do not influence the likelihood of improving fol-
lowing pulmonary rehabilitation. Moreover, patients identified as a psy-
chological cluster with highest scores in anxiety and depression had a
higher likelihood of achieving meaningful improvements after rehabil-
itation [198].
Adherence to all components of comprehensive treatments must be
considered as an important goal for health care providers and patients
to work towards optimal management and control of chronic respira-
tory conditions. Providers play an important role in helping patients to
adhere with all the components of the management plan. Active in-
volvement of the patients in defining management goals and partner-
ship between the patient and the team of health care providers will im-
prove adherence. Future research is needed to gain insights into de-
terminants of adherence and sustainability of adherence during the
continuum of care of these patients.
Medication adherence in patients with COPD
COPD is a chronic disease in which effective management requires
long-term adherence to pharmacotherapies [199]. Regrettably, the
level of medication adherence in COPD patients is very low, lower than
that recorded for other diseases [200], although it must be pointed out
that there are difficulties in understanding the real dimension of the
problem and the causes that determine it because it problematic to
compare the results of different studies carried out.
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Patient-health care professional, especially patient-physician or pa-
tient-pharmacist communication is central to optimizing patient ad-
herence [202]. Education of patients, along with better co-ordination
of care, showed significant improvements on COPD patients’ adher-
ence [215] as well as fewer hospitalizations [216].
Interestingly, pragmatic pharmacist care programs improve both in-
halation technique and medication adherence in patients with COPD
and could reduce hospitalization rates [217]. This is a cost-saving
strategy compared with usual care [218].
No standard intervention exists to improve adherence. However, it is
likely that a multifactorial intervention focuses on motivation, knowl-
edge and skilled inhalation technique (COPD information, dose re-
minders, audio-visual material, motivational aspects and training in in-
halation techniques) is an effective approach to improving the thera-
peutic adherence in COPD patients [219]. In any case, adherence re-
quires a behavioral change, an aspect that is related to individual in-
terests and expectations, meaning that patients must be managed in-
dividually. Furthermore, the intervention is complex and time-con-
suming.
Although more research is needed into the most effective ap-
proaches for optimizing medication adherence in patients, mainly
elders, with COPD, there are a number of practical opportunities for
health care practitioners to intervene to support medication adherence
[220]. However, it is likely that the most realistic approach is to keep
in mind that non-adherence is always possible and probable [208].
Adherence to COPD therapy: The Lombardy 
CREG (Chronic Related Group) experience
CREG can be defined as an innovative way to care patients with
chronic diseases. The innovative element which lead actors to focus
on the life time horizon and think in terms of prevention is the CREG
tariff. Against a payment of a default quota of resources, it must be
ensured all services outside the hospital (outpatient, prosthetics,
pharmaceutical, home care, etc.) required for good clinical and orga-
nizational management of chronic disease – or set of diseases [221]
– and is aimed to ensuring the essential levels included in the var-
ious pathways of care. From the structural point of view, CREG is
composed by three technological elements and an organizational
platform: the first technological element is represented by the ability
to identify the chronic illness; the second one is the PDT (Percorsi
Diagnostici Terapeutici) that is to say the standard guidelines for
any disease or set of diseases and the third one is a system of remu-
neration.
Particularly, there were define diseases of priority interest and
some ASL (Bergamo, Como, Milan downtown, Melegnano, Lecco) in
which to apply the specify path. COPD has considered one of the dis-
eases of main interest [222]. The aim of the test has been to put the
emphasis on the administrative, organizational, and management as-
pects, with the intent of identifying critical aspects, opportunities and
operational solutions [224]. One of the most impressive data was the
COPD therapy adherence. The “pact” between general practitioner
and patient with the help of nurses, reached the goal to equalize the
COPD adherence therapy rate to the diabetes and hypertension rate in
two years [224].
The key aspect of the CREG, is represented by identification of sub-
ject that guarantees the continuity of the path, interacting with all the
actors involved in the management of the disease and ensuring the
necessary administrative, organizational and managerial skills (gen-
eral practitioners, foundations, hospitals, etc.) which will be in charge
for ensuring the full support of patients recruited to the path of CREG.
The most important expected outcome is in terms of the adequacy
and appropriateness of care. That is through two channels: first pa-
tients (hypo consumers) who usually give up their pathway are leading
to adherence to PDT; secondly, by avoiding the inappropriate medical
consumption.
State-of-the-art and open problems in COPD: 
Gaps and issues
The main goals of COPD treatment are reducing current symptoms
and future risks with minimal adverse effects by pharmacological treat-
ments. The achievement of these objectives may be a challenge in daily
clinical practice, where the level of adherence to treatment is low, with
consequent poor control of the disease, and the occurrence of co-mor-
bidities requires multiple drugs, with an increased risk of drug-drug in-
teractions potentially leading to severe adverse effects. In addition, a
significant discrepancy has been reported between guideline recom-
mendations and clinicians’ practices [224-226].
The currently available bronchodilator therapies approved for COPD
are LABA (long-acting or ultra long-acting β-2 agonists) and LAMA (an-
timuscarinic agents). Bronchodilators are the mainstay of COPD treat-
ment, as single agents, as dual combination, or associated with inhaled
corticosteroids (ICS). Until last year, the latter represented the first-
choice treatment for stable COPD in the most severe stages of the dis-
ease (GOLD stage C and D). The newest GOLD recommendations
[103] set the ICS/LABA as alternative choice when exacerbations per-
sist despite treatment with LABA/LAMA. Nevertheless, the manage-
ment of COPD patients by general practitioners (GPs) and by special-
ists in real life settings is often characterized by inappropriateness of
prescribing the ICS/LABA combination in patients with mild or mod-
erate COPD [227]. The use of ICS must be carefully evaluated, since it
has been associated with an increased risk of developing pneumonia,
which is greatest in the very elderly and at the highest doses [227].
A variable proportion of the COPD population does not control the
disease because of factors that include inadequate drug treatment, and
lack of adherence to the recommended drug therapy or to the device. In
addition, physicians and patients tend to underestimate the intensity
and frequency of respiratory symptoms, and the need to monitor the
disease. Overall, the occurrence of inadequate physician-patient com-
munication is the main factor that contributes to the lack of optimal
control. The lack of adherence to therapy strongly impacts on the con-
trol of the disease. Indeed, the aim of inhaled therapy is to allow the
medication to reach the target site. This can be attained by ensuring
the penetration of the aerosolized particles into the lower respiratory
tract, and the deposition of the drug along the bronchial tree. Obviously,
the deposition of the drug should translate into functional and clinical
benefits. Taken together, these conditions lead to the fact that the right
choice of the (right) device becomes crucial. The devices differ in
terms of technical design (required inspiratory flow rate, actuation),
composition (characteristics of the propellant, carrier substances),
dose per inhalation, and costs. In addition, major efforts have been de-
voted by the producer on the user-friendliness of the device [61]. The
relative deposition pattern of the inhaled drug is the result of a complex
interaction between the aerosol formulation and the device used. In the
suspension formulation, the active drug is not-soluble in the propellant
and remains as solid powder; therefore, suspension formulations need
to be shaken before inhalation to allow uniform distribution of solid
powder particles of the drug. It has been demonstrated that a signifi-
cant proportion of patients do not shake properly the device or present
with coordination problems [228], resulting in variable amount of
emitted drug in each aerosol puff. The occurrence of mistakes associ-
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ated with the inhalation procedures can be reasonably reduced by reg-
ular training and follow-up. Patients are not completely satisfied with
physician behaviors, and often do not trust the pharmacological treat-
ment. Therefore, the choice of the inhaler is the result of an alliance
between the physician and the patient, who agree on the needs and ex-
pectations. Not all device can fit the patients’ skills; as discussed below,
the concomitant extra-pulmonary conditions and older ages can vari-
ably affect the ability to properly use the inhaler [229].
Another reason for the inadequate control of COPD has to be identi-
fied in the unsatisfactory collaboration between specialists and GPs. In
this regard, a recent explorative investigation showed that imple-
menting the collaboration between GPs and pulmonologists may en-
hance the diagnostic process towards COPD [230]. The so-called
“COPD action” experience based on a pro-active approach to the indi-
viduals attending the primary care offices followed by an in-house in-
tervention by specialists could serve as a model for larger interven-
tional approaches to unveil undiagnosed chronic obstructive lung dis-
eases. One of the gaps that needs to be filled is the implementation of
the use of lung function assessment in individuals with suspected
COPD and/or in the follow-up of subjects with an ascertain diagnosis of
COPD. In this respect, although international guidelines recognize the
use of spirometry as the gold standard for confirming the presence of
irreversible airflow limitation and diagnosing COPD in reproducible,
standardized, and objective way, only a proportion of GPs has been
shown to use spirometric criteria to define COPD [231].
COPD is characterized by the presence of comorbid conditions. Co-
morbidities have a potent influence on the therapeutic management of
COPD. Due to the prevalence of early onset of comorbidities in COPD,
an early treatment of the disease could be suggested to prevent the
burden of comorbid conditions, even if further studies are still required
to confirm the efficacy of this approach. For example, an increased risk
of cardiovascular disorders has been recently documented in smoker
subjects who are symptomatic but have not developed airway obstruc-
tion [232]. It has been suggested that the long-lasting exposure to
smoke is the driving factor that initiates the inflammatory process both
in the lungs and in the arteries, which in turn promotes the excess car-
diovascular risk in chronic respiratory patients.
Clinical practice guidelines, the backbones of evidence-based medi-
cine, are based upon the results of meta-analyses and randomized clin-
ical trials (RCTs). In order to exclude potential confounding factors
that may affect the results of the RCTs, restrictive inclusion/exclusion
criteria are usually applied for recruitment of the sample. However,
highly selected “pure” study populations might not be fully representa-
tive of larger, unselected, patients attending the outpatient clinics in
the real-life setting. As a consequence, the extrapolation of the RCTs
results to the everyday clinical practice could be potentially limited. In
asthma, more than 40% of subjects with mild/moderate disease are cur-
rently treated by protocols based on the results of RCTs for which they
would have not been eligible [233]. This proportion increases in eld-
erly patient with comorbidities. In COPD, more than 80% of subjects
with COPD are currently treated by protocols based on results of RCTs
for which they would have not been eligible [234]. These findings limit
the generalizability of RCTs and advocate for complementary pragmatic
studies.
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